EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Tunlametinib: First Approval

Susan J Keam

Drugs · 2024-08 · 84 (8) · 1005-1010

DOI: 10.1007/s40265-024-02072-x ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Drugs, online erschienen am 22.07.2024. Verfasst von Susan J Keam. Beteiligte Einrichtung: Springer Nature, Mairangi Bay, Private Bag 65901, Auckland, 0754, New Zealand. dru@adis.com. Hauptthemen laut MEDLINE: Drug Approval, Protein Kinase Inhibitors. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 15 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Tunlametinib (®) is an oral, selective, mitogen-activated protein kinase kinase 1 and 2 (MEK 1/2) inhibitor being developed by Shanghai KeChow Pharma, Inc. for the treatment of solid tumours with RAS and RAF mutations, including melanoma, non-small cell cancer (NSCLC), colorectal cancer (CRC) and neurofibromatosis type 1 (NF1) plexiform neurofibromas. In March 2024, tunlametinib was granted conditional approval in China (based on surrogate endpoints) for use in patients with NRAS-mutated advanced melanoma who have failed anti-PD-1/PD-L1 treatment. This article summarizes the milestones in the development of tunlametinib leading to this first approval for the treatment of solid tumours with RAS and RAF mutations.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Drug ApprovalProtein Kinase InhibitorsHumansAntineoplastic AgentsMutationMelanomaColorectal NeoplasmsCarcinoma, Non-Small-Cell LungNeoplasmsMAP Kinase Kinase 1

Substanzen

Protein Kinase InhibitorsAntineoplastic AgentsMAP Kinase Kinase 1

Autor:innen und Institutionen

  • Springer Nature, Mairangi Bay, Private Bag 65901, Auckland, 0754, New Zealand. dru@adis.com.

Zitieren

APA

Keam, S. J. (2024). Tunlametinib: First Approval. Drugs, 84(8), 1005-1010. https://doi.org/10.1007/s40265-024-02072-x

Vancouver

Keam SJ. Tunlametinib: First Approval. Drugs. 2024;84(8):1005-1010. doi:10.1007/s40265-024-02072-x

BibTeX
@article{Keam2024,
  author = {Keam, Susan J},
  title = {Tunlametinib: First Approval},
  journal = {Drugs},
  year = {2024},
  volume = {84},
  number = {8},
  pages = {1005--1010},
  doi = {10.1007/s40265-024-02072-x}
}
Kostenlos starten →